This site is intended for healthcare professionals
Drug news

Vertex Pharma initiates Phase III study for VX 659 + tezacaftor + ivacaftor to treat F508del mutation cystic fibrosis.

Read time: 1 mins
Last updated:27th Feb 2018
Published:27th Feb 2018
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest